IDEXX Laboratories (IDXX) Expected to Announce Earnings on Monday

IDEXX Laboratories (NASDAQ:IDXX) will likely be releasing its Q4 2025 results before the market opens on Monday, February 2nd. Analysts expect IDEXX Laboratories to post earnings of $2.93 per share and revenue of $1.0723 billion for the quarter. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, February 2, 2026 at 8:30 AM ET.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the company posted $2.80 EPS. The company’s revenue was up 13.3% compared to the same quarter last year. On average, analysts expect IDEXX Laboratories to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $670.46 on Friday. The company has a 50-day moving average price of $705.35 and a 200 day moving average price of $659.88. IDEXX Laboratories has a 12-month low of $356.14 and a 12-month high of $769.98. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24. The stock has a market cap of $53.54 billion, a P/E ratio of 53.17, a PEG ratio of 3.61 and a beta of 1.67.

Insider Activity

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.98% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Kelleher Financial Advisors boosted its holdings in IDEXX Laboratories by 3.1% in the third quarter. Kelleher Financial Advisors now owns 832 shares of the company’s stock valued at $532,000 after acquiring an additional 25 shares during the last quarter. NewEdge Advisors LLC raised its holdings in shares of IDEXX Laboratories by 1.1% during the third quarter. NewEdge Advisors LLC now owns 2,680 shares of the company’s stock worth $1,712,000 after purchasing an additional 28 shares during the period. Advisory Services Network LLC lifted its holdings in shares of IDEXX Laboratories by 4.2% in the 2nd quarter. Advisory Services Network LLC now owns 743 shares of the company’s stock worth $397,000 after purchasing an additional 30 shares during the last quarter. Virtus Advisers LLC acquired a new position in IDEXX Laboratories during the 3rd quarter valued at about $26,000. Finally, Smartleaf Asset Management LLC grew its stake in shares of IDEXX Laboratories by 5.9% in the second quarter. Smartleaf Asset Management LLC now owns 806 shares of the company’s stock worth $428,000 after purchasing an additional 45 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. BTIG Research increased their price objective on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. JPMorgan Chase & Co. increased their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a report on Monday, November 3rd. Finally, Leerink Partners set a $785.00 price target on IDEXX Laboratories in a research note on Monday, November 3rd. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $763.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.